Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Respiratory (Asthma/COPD) (Oct 2017)

Posted by Matt Breese on Oct 6, 2017

Find me on:

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Coverage is primarily medical benefit (below) but some payers include products on their formulary, making pharmacy benefit relevant. Under pharmacy benefits, medicare saw a recent surge in average restricted lives over the past quarter.

mmit-reality-check-respiratory-4q2017.png

Source: MMIT data as of Q4 2017

Trends:  Recent news related to asthma/COPD treatments show that with more biologics entering the market, contracting will be more prevalent - whereas it’s minimal today. 

To read the full Reality Check on respiratory with key findings on clinical characteristics, asthma/COPD drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

 

Topics: Specialty, Market Access, Branding & Marketing